SHELTON, Conn., June 20, 2017 /PRNewswire/ --
NanoViricides, Inc., (NYSE MKT: NNVC ) (the "Company"), a pioneer in developing anti-viral nanomedicine
drugs, is pleased to announce that its late-breaking abstract submission has been accepted for a poster presentation at the 36th
Annual Meeting of the American Society of Virology (ASV). The ASV Meeting will be hosted and held at the University of Wisconsin-Madison, from June 24th to 28th, 2017 ( https://extensionconferencecenters.uwex.edu/asv2017/ ).
Dr. Brian Friedrich, Senior Virologist of the Company, will present the Company's work on
the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka
Human HerpesVirus-3 or HHV-3). He will present data on both safety and effectiveness of the nanoviricides drug candidates against
VZV infection in multiple different cell lines.
NanoViricides has recently announced that two of the HerpeCide™ program drug candidates demonstrated complete
(almost 100%) inhibition of the varicella-zoster virus (VZV, aka human herpesvirus 3 or HHV-3) at highest drug doses, whereas
acyclovir at the same drug dose exhibited only about 70% inhibition of the virus. The nanoviricide drug candidates were almost
five times as effective as acyclovir in these assays. No cytotoxicity was observed at any of the doses tested for the herpecide
drug candidates. Details of these studies will be presented in the poster at the 2017 Annual Meeting of the ASV.
The NanoViricides poster, entitled "Novel Nanoviricides® Highly Effective against Varicella Zoster Virus in Cell Culture" will
be presented in Poster Session II, open for viewing from 4pm to 6pm on Monday, June 26th, 2017.
About NanoViricides :
NanoViricides,
Inc. ( www.nanoviricides.com ) is a development stage company that is creating special
purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future
events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors.
Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties
and other factors that are, in some cases, beyond the Company's control and which could, and likely will, materially affect
actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise
these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that
could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors
that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the
United States Securities and Exchange Commission.. Although it is not possible to predict or identify all such factors,
they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of
our products.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanoviricides-abstract-accepted-for-poster-presentation-at-the-2017-annual-meeting-of-american-society-of-virology-300476401.html
SOURCE NanoViricides, Inc.